FUB-144
Synthetic CB1 and CB2 agonist, not named in France but covered by a generic clause.
C₂₃H₂₄FNO
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
Data sheet
Names
- IUPAC name
- [1-[(4-fluorophenyl)methyl]indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone
- Other names
- FUB-UR-144
Identifiers
- Formula
- C₂₃H₂₄FNO
- Molar mass
- 349.40 g/mol
- CAS
- 2185863-15-2
- PubChem CID
- 118796439(new tab)
- InChIKey
- UXOFEILQVZFLRH-UHFFFAOYSA-N
Class
- Family
- Synthetic cannabinoid (SCRA)
Updated on
Receptors and activity
- CB1Agonist76 out of 100
Ki 27,2 nM ; EC50 90,6 nM en GTPγS (Marusich et coll., 2022, récepteur humain recombinant)
- CB2Agonist90 out of 100
Ki 1,19 nM ; EC50 4,61 nM en GTPγS (Marusich et coll., 2022, récepteur humain recombinant)
Subjective signature
- Calm
- 5 out of 100
- Relaxation of body and mind; reduced mental noise without marked drowsiness.
- Clarity
- 3 out of 100
- Sustained attention and clear thinking; functional lucidity, not euphoria.
- High
- 5 out of 100
- Euphoria and sensory intensity; altered perception of time and space.
- Appetite
- 3 out of 100
- Stimulation of hunger and of taste appreciation (the “munchies” effect).
- Sleep
- 5 out of 100
- Sedative effect: aids sleep onset and the continuity of deep sleep.
Pharmacology
FUB-144, also called FUB-UR-144, is a synthetic cannabinoid of the tetramethylcyclopropanoylindole family, with the systematic name [1-[(4-fluorophenyl)methyl]indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone. On recombinant human receptors it binds CB1 with a Ki of 27.2 nM and CB2 with a Ki of 1.19 nM, meaning higher affinity for CB2 (Marusich et al., 2022). It has been studied as a constituent of herbal incense blends known as spice (Hess et al., 2016) and identified in seizures (Al-Matrouk and Orabi, 2025). No human pharmacokinetic or toxicological data are published. In France it is not named in the list of narcotics but falls under a generic clause, the 'Indol-3-yl methanone' definition.
Key sources.
- Marusich et coll., Pharmacologie in vitro et in vivo de neuf agonistes synthétiques des récepteurs cannabinoïdes, Pharmacol Biochem Behav 2022 (new tab)PMID 36154844
- Hess et coll., Évaluation pharmacologique de cannabinoïdes de synthèse identifiés comme constituants de spice, Forensic Toxicol 2016 (new tab)PMID 27429655
- Kim et coll., Métabolisme in vitro et in vivo du FUB-144 par UHPLC-HRMS, Arch Toxicol 2026 (new tab)PMID 41807793
- Shetty et coll., Pharmacologie comportementale de cannabinoïdes de synthèse indazole, indole et benzimidazole, J Cannabis Res 2026 (new tab)PMID 41526973
- Al-Matrouk et Orabi, Identification de cannabinoïdes de synthèse saisis au Koweït (2019-2023) par RMN, Forensic Sci Res 2025 (new tab)PMID 40302876
- ANSM, Liste consolidée des substances classées comme stupéfiants (mise à jour du 16 février 2026) (new tab)
- INCB, Green List 2026 (substances des conventions de 1971) (new tab)
- PubChem, CID 118796439 (FUB-144) (new tab)
History
- Source
- Synthetic compound with no plant or animal origin. It was identified in seizures: two samples seized in Kuwait between 2019 and 2023 were identified as FUB-144 by NMR (Al-Matrouk and Orabi, 2025). Hess et al. (2016) studied it among synthetic cannabinoids identified as constituents of spice blends.
Origin (pharmaceutical research → illicit market)
No biosynthetic pathway: synthetic compound of the tetramethylcyclopropanoylindole class.
Legal framework
- European Union
No harmonised European Union control measure is documented for this compound in the sources consulted.
- France
FUB-144 is not named in the consolidated French list of narcotics (updated 16 February 2026). It does fall under the generic definition 'Indol-3-yl methanone' (Annex IV, page 41 of the PDF): the indole nitrogen carries a halobenzyl substituent (here a 4-fluorobenzyl) and the methanone carbon carries a cyclopropyl group, substituted or not (here a 2,2,3,3-tetramethylcyclopropyl). Both conditions are met, so the compound is covered by this clause.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
References
- Marusich et coll., Pharmacologie in vitro et in vivo de neuf agonistes synthétiques des récepteurs cannabinoïdes, Pharmacol Biochem Behav 2022 (new tab)PMID 36154844
- Hess et coll., Évaluation pharmacologique de cannabinoïdes de synthèse identifiés comme constituants de spice, Forensic Toxicol 2016 (new tab)PMID 27429655
- Kim et coll., Métabolisme in vitro et in vivo du FUB-144 par UHPLC-HRMS, Arch Toxicol 2026 (new tab)PMID 41807793
- Shetty et coll., Pharmacologie comportementale de cannabinoïdes de synthèse indazole, indole et benzimidazole, J Cannabis Res 2026 (new tab)PMID 41526973
- Al-Matrouk et Orabi, Identification de cannabinoïdes de synthèse saisis au Koweït (2019-2023) par RMN, Forensic Sci Res 2025 (new tab)PMID 40302876
- ANSM, Liste consolidée des substances classées comme stupéfiants (mise à jour du 16 février 2026) (new tab)
- INCB, Green List 2026 (substances des conventions de 1971) (new tab)
- PubChem, CID 118796439 (FUB-144) (new tab)
Structured data
- SMILES
- CC1(C(C1(C)C)C(=O)C2=CN(C3=CC=CC=C32)CC4=CC=C(C=C4)F)C
- InChIKey
- UXOFEILQVZFLRH-UHFFFAOYSA-N
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.